New drug to stop ‘Ozempic butt’ muscle loss side effect of obesity jabs

• Weight loss from GLP-1 receptor agonists results in approximately 33% muscle loss alongside fat loss, necessitating clinical attention to body composition changes
• A new pharmacological intervention is in development to mitigate muscle wasting associated with obesity medications, addressing a significant adverse effect
• Clinicians should counsel patients on GLP-1 therapy regarding muscle preservation strategies and monitor for sarcopenia risk, particularly in older or frail populations

A third of the weight loss from obesity jabs can come from muscle, say experts.

ClinicaliQ summarises and contextualises external updates for clinical awareness, then links to the original publisher for the full article and most current context.